They always keep a bag packed. They seldom have more than twenty-four hours' notice before they are dispatched. The phone calls that tell them to head to the airport, sometimes in the middle of the night, may give them no more information than the country they are traveling to and the epidemic they will tackle when they get there.The universal human instinct is to run from an outbreak of disease. These doctors run toward it.They are the disease detective corps of the U.S. Centers for Disease Control and Prevention (CDC), the federal agency that tracks and tries to prevent disease outbreaks and bioterrorist attacks around the world. They are formally called the Epidemic Intelligence Service (EIS) -- a group founded more than fifty years ago out of fear that the Korean War might bring the use of biological weapons -- and, like intelligence operatives in the traditional sense, they perform their work largely in anonymity. They are not household names, but over the years they were first to confront the outbreaks that became known as hantavirus, Ebola virus, and AIDS. Now they hunt down the deadly threats that dominate our headlines: West Nile virus, anthrax, and SARS.In this riveting narrative, Maryn McKenna -- the only journalist ever given full access to the EIS in its fifty-three-year history -- follows the first class of disease detectives to come to the CDC after September 11, the first to confront not just naturally occurring outbreaks but the man-made threat of bioterrorism. They are talented researchers -- many with young families -- who trade two years of low pay and extremely long hours for the chance to be part of the group that has helped eradicate smallpox, push back polio, and solve the first major outbreaks of Legionnaires' disease, toxic shock syndrome, and "E. coli" O157.Urgent, exhilarating, and compelling, "Beating Back the Devil" goes with the EIS as they try to stop epidemics -- before the epidemics stop us.

    America faced a troubling question: What happened? How was this epidemic allowed to spread so far before it was taken seriously? In answering these questions, Shilts weaves the disparate threads into a coherent story, pinning down every evasion and contradiction at the highest levels of the medical, political, and media establishments. Shilts shows that the epidemic spread wildly because the federal government put budget ahead of the nation's welfare; health authorities placed political expediency before the public health; and scientists were often more concerned with international prestige than saving lives. Against this backdrop, Shilts tells the heroic stories of individuals in science and politics, public health and the gay community, who struggled to alert the nation to the enormity of the danger it faced. And the Band Played On is both a tribute to these heroic people and a stinging indictment of the institutions that failed the nation so badly.

    The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

    This book is the most engaging, focused and applied HRM text on the market.

    The text integrates contemporary research in biology, psychology, anthropology and sociology, utilizing the biopsychosocial model as the basic explanatory theme for health and health care. Gender, sociocultural and developmental differences in health and related behaviours are also integrated throughout the text. This systems approach is complemented by the integration of life-span development in health and illness in each chapter of the text.

    We like to imagine that it’s based on evidence and the results of fair tests. In reality, those tests are often profoundly flawed. We like to imagine that doctors are familiar with the research literature surrounding a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by industry. We like to imagine that regulators let only effective drugs onto the market, when in reality they approve hopeless drugs, with data on side effects casually withheld from doctors and patients.All these problems have been protected from public scrutiny because they’re too complex to capture in a sound bite. But Dr. Ben Goldacre shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct on a global scale affects us. In his own words, “the tricks and distortions documented in these pages are beautiful, intricate, and fascinating in their details.” With Goldacre’s characteristic flair and a forensic attention to detail, Bad Pharma reveals a shockingly broken system and calls for something to be done. This is the pharmaceutical industry as it has never been seen before.

    This book introduces you to R, RStudio, and the tidyverse, a collection of R packages designed to work together to make data science fast, fluent, and fun. Suitable for readers with no previous programming experience, R for Data Science is designed to get you doing data science as quickly as possible. Authors Hadley Wickham and Garrett Grolemund guide you through the steps of importing, wrangling, exploring, and modeling your data and communicating the results. You’ll get a complete, big-picture understanding of the data science cycle, along with basic tools you need to manage the details. Each section of the book is paired with exercises to help you practice what you’ve learned along the way. You’ll learn how to: Wrangle—transform your datasets into a form convenient for analysis Program—learn powerful R tools for solving data problems with greater clarity and ease Explore—examine your data, generate hypotheses, and quickly test them Model—provide a low-dimensional summary that captures true "signals" in your dataset Communicate—learn R Markdown for integrating prose, code, and results

    Bill Gates, Bono, and Laura Bush are only a few of the personalities who have lent their names--and opened their pocketbooks--in hopes of curing the disease. Still, in a time when every emergent disease inspires waves of panic, why aren't we doing more to eradicate one of our oldest foes? And how does a parasitic disease that we've known how to prevent for more than a century still infect 500 million people every year, killing nearly 1 million of them? In "The Fever," the journalist Sonia Shah sets out to answer these questions, delivering a timely, inquisitive chronicle of the illness and its influence on human lives. Through the centuries, she finds, we've invested our hopes in a panoply of drugs and technologies, and invariably those hopes have been dashed. From the settling of the New World to the construction of the Panama Canal, through wars and the advances of the Industrial Revolution, Shah tracks malaria's jagged ascent and the tragedies in its wake, revealing a parasite every bit as persistent as the insects that carry it. With distinguished prose and original reporting from Panama, Malawi, Cameroon, India, and elsewhere, "The Fever" captures the curiously fascinating, devastating history of this long-standing thorn in the side of humanity.

    This clear, concise look at the basic principles and concepts of genetics uses a human genetics perspective to discuss the methods and experiments upon which genetic principles are based, such as DNA replication.

    Dr. Makary, one of the nation's leading health care experts, travels across America and details why health care has become a bubble. Drawing from on-the-ground stories, his research, and his own experience, The Price We Pay paints a vivid picture of price-gouging, middlemen, and a series of elusive money games in need of a serious shake-up. Dr. Makary shows how so much of health care spending goes to things that have nothing to do with health and what you can do about it. Dr. Makary challenges the medical establishment to remember medicine's noble heritage of caring for people when they are vulnerable.The Price We Pay offers a roadmap for everyday Americans and business leaders to get a better deal on their health care, and profiles the disruptors who are innovating medical care. The movement to restore medicine to its mission, Makary argues, is alive and well--a mission that can rebuild the public trust and save our country from the crushing cost of health care.

    In the new edition of Biochemistry, instructors will see the all the hallmark features that made this a consistent bestseller for the undergraduate biochemistry course: exceptional clarity and concision, a more biological focus, cutting-edge content, and an elegant, uncluttered design.  Accomplished in both the classroom and the laboratory, coauthors Jeremy Berg and John Tymoczko draw on the field's dynamic research to illustrate its fundamental ideas.

    The text is non-threatening and presents concepts clearly and succinctly with a conversational writing style. All statistical concepts are illustrated with solved applied examples immediately upon introduction. Self reviews and exercises for each section, and review sections for groups of chapters also support the student learning steps. Modern computing applications (Excel, Minitab, and MegaStat) are introduced, but the text maintains a focus on presenting statistics concepts as applied in business as opposed to technology or programming methods. The thirteenth edition continues as a students' text with increased emphasis on interpretation of data and results.

    Improper use of antibiotics. Local warfare. Massive refugee migration. Changing social and environmental conditions around the world have fostered the spread of new and potentially devastating viruses and diseases—HIV, Lassa, Ebola, and others. Laurie Garrett takes you on a fifty-year journey through the world's battles with microbes and examines the worldwide conditions that have culminated in recurrent outbreaks of newly discovered diseases, epidemics of diseases migrating to new areas, and mutated old diseases that are no longer curable. She argues that it is not too late to take action to prevent the further onslaught of viruses and microbes, and offers possible solutions for a healthier future.

    Designed for graduate and advanced undergraduate students, it includes the contributions of leading thinkers, educators, and practitioners who provide an in-depth and objective appraisal of why and how we organize health care the way we do; the enormous impact of health-related behaviors on the structure, function, and cost of the health care delivery system; and other emerging and recurrent issues in health policy, health care management, and public health. To update this book with the rapid changes that have occurred in health care through November 2013, a separate chapter, the Affordable Care Act (ACA) Supplement, is available to students and instructors as a downloadable PDF.This text is divided into five sections, in order to provide some coherence to this broad terrain. Part I, The Current U.S. Health Care System, addresses major characteristics and issues, including reform, financing, and comparative health care systems. This section now includes multiple new charts and tables providing concrete health care data. Part II, Population Health, focuses on health behavior, including health care models, public health policy and practice, risk factors, facilitating healthy lifestyle practices, and access to care. Part III, Medical Care Delivery, addresses integrated health models, delivering high-quality health care, health care costs and value, and comparative effectiveness. Part IV, Support for Medical Care Delivery, concerns governance and management issues, including accountability, the health workforce, and information technology. Part V, The Future of Health Care Delivery in the United States, includes a new 5-year trend forecast.Key Features: Includes major provisions of the Patient Protection and Affordable Health Care Act of 2010Each chapter includes these special features: key concepts; extensive mapping resources; key words; learning objectives; discussion questions; and case studiesCovers the newest models of care, such as Accountable Care Organizations and Integrated Delivery SystemsExamines new ways of conceptualizing and assessing health care, including comparative effectiveness researchFeatures contributions by leading scholars and key figures within the U.S. health care system, including John Billings, JD; Carolyn M. Clancy, MD; C. Tracy Orleans, PhD; and Michael S. Sparer, PhD, JDContains new coverage of health reform, developing countries, population health, public health and catastrophic events, and a broadened discussion of the health care workforceAffordable Care Act (ACA) Supplement available to students and instructors as a downloadable PDF. Available to Instructors: Instructor's Guide (updated to reflect content from ACA supplement)PowerPoint PresentationsImage BankTest Bank (updated to reflect content from ACA supplement)"

    Focused more on concepts than on statistical methods, it shows readers how to properly use statistics to analyze data and demonstrates how computer software is an integral part of this analysis. "Using Statistics" scenarios discuss how statistics is used in a real business setting. Includes contemporary business applications, many with real data sets, and an integrated case that runs throughout chapters. "PHSTAT," a custom designed Excel add-in, is packaged with each book. Introduction and Data Collection. Presenting Data in Tables and Charts. Summarizing and Describing Numerical Data. Basic Probability and Probability Distributions. Sampling Distributions and Confidence Interval Estimation. Fundamentals of Hypothesis Testing: One-Sample Tests. Two-Sample and C-Sample Tests with Numerical Data. Hypothesis Testing with Categorical Data. Statistical Applications in Quality and Productivity Management. The Simple Linear Regression Model and Correlations. Introduction to Multiple Regression. Time Series Analysis. An accessible introduction or refresher on statistics for those in accounting, marketing, management, economics, and finance.